Levamisole in relapsing steroid-sensitive nephrotic syndrome: where do we stand?
- PMID: 29389398
- DOI: 10.1016/j.kint.2017.09.024
Levamisole in relapsing steroid-sensitive nephrotic syndrome: where do we stand?
Abstract
Many patients with steroid-sensitive nephrotic syndrome develop a relapsing course; therefore, alternative treatment may be necessary to avoid steroid toxicity. In this issue, a multicenter controlled study in relapsing steroid-sensitive nephrotic syndrome shows the effectiveness of levamisole. Time to first relapse was significantly increased compared with placebo. In addition, possible differential treatment effects were suggested for subgroups: patients with frequent relapses might have a superior response to those with steroid dependency.
Copyright © 2017 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.
Comment on
-
A randomized clinical trial indicates that levamisole increases the time to relapse in children with steroid-sensitive idiopathic nephrotic syndrome.Kidney Int. 2018 Feb;93(2):510-518. doi: 10.1016/j.kint.2017.08.011. Epub 2017 Oct 18. Kidney Int. 2018. PMID: 29054532 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources